cp wire

CP Wire Articles

  • Rezafungin has fast track and Qualified Infectious Disease Product (QIDP) designations to rezafungin for for the prevention of invasive fungal infections in adults undergoing allogeneic bone... read more
Thu, 09/27/18 - 10:23 am

CytoSen Therapeutics, a private biopharmaceutical company accelerating innovation in Natural Killer (NK) cell therapy, announced on 9/27/18 it has received a favorable response from the U.S. Food... read more

Thu, 09/27/18 - 09:57 am
  • Percepta relies on cells taken during a normal bronchoscopy
  • Envisia uses patient samples that are obtained using transbronchial biopsy

Veracyte, Inc. (NASDAQ: VCYT)... read more

Thu, 09/27/18 - 09:36 am
  • LYR-210 has the potential to be the first approved drug product for CRS
  • The product can deliver relief for up to six months
  • In the United States, chronic rhinosinusitis has... read more
Wed, 09/26/18 - 09:49 am

Proscia announced on 9/26/18 that it has closed an $8.3 million round of Series A financing from a group of East and West Coast venture capital firms. The funding was led by Boston-based Flybridge... read more

Wed, 09/26/18 - 09:29 am
  • Edasalonexent has orphan drug status in the US and Europe
  • It has been fast-track status in the US

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) announced on 9/25/18 the... read more

Tue, 09/25/18 - 10:12 am
  • Imfinzi is currently approved in the US for the treatment of patients with unresectable Stage III NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy and... read more
Tue, 09/25/18 - 09:51 am
  • Alunbrig achieved a 51% increase in progression free survival compared to crizotinib
  • Alunbrig received Breakthrough Therapy Designation from the FDA for the treatment of patients... read more
Tue, 09/25/18 - 09:33 am
  • Oral mucositis is potentially a 1 billion dollar market
  • Additional expenses incurred by patients suffering from SOM are estimated to be as high as $18,000 to $25,000 per case in the... read more
Mon, 09/24/18 - 10:13 am

AstraZeneca on 9/24/18 announced positive results from the Phase III DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for Farxiga (dapagliflozin), the broadest SGLT-2 inhibitor CVOT... read more

Mon, 09/24/18 - 09:36 am

Gilead Sciences, Inc. (NASDAQ: GILD) announced on 9/24/18 plans to launch authorized generic versions of Epclusa (sofosbuvir 400mg/velpatasvir 100mg) and Harvoni (ledipasvir 90mg/sofosbuvir... read more

Mon, 09/24/18 - 09:22 am
  • Exelixis is eligible to receive a milestone payment of $40 million for the approval of the second-line treatment of HCC
  • In May of 2018, the FDA accepted for filiing an sNDA for... read more
Fri, 09/21/18 - 09:42 am
  • Company expanding into drug discovery, development and commercialization
  • Ubiome also announced it has raised $83 million in Series C financing

uBiome announced on 9/... read more

Fri, 09/21/18 - 09:15 am

MicuRx Pharmaceuticals, Inc. announced on 9/21/18 the receipt of the qualified infectious disease product (QIDP) classification and grant of fast track... read more

Fri, 09/21/18 - 09:05 am
  • The objective response rate was 29 percent (4 of 22 patients)
  • BeiGene and Celgene Corporation have a global strategic collaboration for the development of tislelizumab in solid tumor... read more
Thu, 09/20/18 - 09:47 am
  • Amicus will make an upfront cash payment of $100 million
  • The company also announced closing a $150 million term loan to help finance the acquisition and development costs
  • ... read more
Thu, 09/20/18 - 09:31 am
  • The vaccine was awarded fast-track status by the FDA in October of 2017
  • Pfizer expects to start Phase 3 trials in a few months

Pfizer Inc. (NYSE:PFE) announced on 9/... read more

Thu, 09/20/18 - 09:08 am

MaaT Pharma announced on 9/18/19 the presentation of the analysis of MaaT Pharma’s lead biotherapeutic, MaaT013, demonstrating its drug product characteristics using MaaT Pharma’s proprietary big... read more

Wed, 09/19/18 - 10:57 pm


current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.